A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose Ranging Study to Evaluate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Cobicistat-boosted GSK2838232 Monotherapy Over 10 Days in HIV-1 Infected Treatment-naive Adults
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Cobicistat (Primary) ; GSK 2838232 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors GlaxoSmithKline
- 22 May 2017 Planned End Date changed from 19 Jun 2017 to 13 Nov 2017.
- 22 May 2017 Planned primary completion date changed from 2 May 2017 to 13 Nov 2017.
- 13 Apr 2017 Planned End Date changed from 2 May 2017 to 19 Jun 2017.